This article is more than 5 years old. Information may no longer be current.

Santen announces positive 24-week data on Ikervis

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Interim data from the PERSPECTIVE study showed statistically significant improvements in patients with severe keratitis who were treated with Ikervis, Santen announced in a press release.

Ikervis (cyclosporine A 0.1% eye drop emulsion) was effective, well tolerated and safe in dry eye and severe keratitis patients at 24 weeks, the release said.

Corneal fluorescein staining grade significantly improved by 77.4% at week 24, while tear breakup time also showed significant improvements.

Treatment-related adverse events were mostly localized at the administration site, and 67.7% were recovered without issue, the release said.